Text Size: A- A+ Facebook Twitter LinkedIn YouTube

Breaking News



Format: 04/16/2014
Format: 04/16/2014


Seattle Times: Medicare weighs if it will cover costly prostate vaccine

Monday, November 29th, 2010

For nearly a decade, many men with prostate cancer have followed the slow progress of the U.S. Food and Drug Administration's approval process for Provenge. In April it became the first therapeutic cancer vaccine approved by the FDA after clinical trials showed it added, on average, four months to recipients' life expectancy.

Prostate cancer Experts from the West Penn Allegheny Health System discuss the potential of Provenge in this Seattle Times published report.

West Penn Allegheny Health System
Tell us who you are:

What areas do you use on our website?*
(select more than one if it applies)

Did you find what you were looking for?

Would you refer others to our website?

Can we contact you for future questions?

CAPTCHA math question:* 1 + 5 =

Thank you for completing the West Penn Allegheny Health System website survey.
We value your feedback and comments.